← Eichor
Study identifier: NCT07644013 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prospective Multicenter Registry Study of Multiple System Atrophy in China

Condition: Multiple System Atrophy · Parkinson's Disease · Atypical Parkinsonism  ·  Sponsor: Peking University First Hospital

PhaseN/A
Planned participants214
Who can joinAll sexes, 40 Years to 75 Years
Healthy volunteersYes

About this study

Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited. This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.

This description comes directly from the study's public registry record.

Talk to the study team

Yunchuang Sun, MD  ·  sychuang0805@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University First HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07644013